Fifteen-minute consultation: Management of the infant born to a mother with toxoplasmosis in pregnancy


ABSTRACT
Congenital toxoplasmosis occurs following transplacental transfer of Toxoplasma gondii. Irrespective of symptom status at birth, infants with congenital infection may develop serious long-term sequelae, including learning disability, seizures, hydrocephalus, motor and hearing deficits, chorioretinitis and retinal scarring with impaired vision. Timely diagnosis facilitates early initiation of therapy, aimed at prevention or amelioration of adverse clinical consequences. Diagnosis can be difficult, however, since acutely infected mothers are often asymptomatic and laboratory testing can be complex. Moreover, any decision to start treatment in the newborn must include careful consideration of the benefits and risks. This paper outlines a structured approach for managing an infant born to a woman with possible or confirmed T. gondii infection during pregnancy, including key aspects of the antenatal history, interpretation and timing of investigations, treatment and appropriate follow-up. Our recommendations are based on current evidence in the literature, consensus from two UK paediatric infectious disease centres and the UK specialist Toxoplasma Reference Unit.

Epidemiology and transmission
Congenital toxoplasmosis (CT) occurs when Toxoplasma gondii, an intracellular protozoan parasite, infects the fetus transplacentally. Worldwide, the estimated incidence of CT ranges from 0.1 to 6 cases per 1000 live births, with the highest burden in the Middle East and South America. However, the current systems for monitoring CT vary across different settings, precluding accurate estimates; in England and Wales, for example, there are no prenatal nor postnatal screening programmes, although enhanced surveillance reports approximately 7–10 confirmed cases annually (online supplementary table 1).

T. gondii can be transmitted to humans by consumption of raw or poorly cooked meat containing viable tissue cysts, ingestion of water or food contaminated by oocysts excreted in cat faeces, vertical transmission of T. gondii during pregnancy, or by transplantation of tissues from an infected donor to an uninfected recipient. The risk of vertical transmission is dependent on gestational age at the time of primary maternal infection and may be reduced by antenatal treatment. For untreated women, the transmission rate is approximately 10%–15% in the first trimester rising to 70%–80% by the third trimester; severity of outcome to the infant, however, is greatest if transmission occurs in the first trimester. In immunocompromised women, CT may occur following reactivation of a previously latent infection.

The differential diagnosis of CT mainly includes other congenital infections (eg, cytomegalovirus, rubella, syphilis, varicella) and conditions that cause retinal lesions and/or intracranial calcifications.

A systematic approach to management
In cases where maternal serology is suggestive of recent toxoplasmosis (eg, positive T. gondii-specific IgG and IgM results) and there is, therefore, a risk of CT, a systematic strategy should be adopted to evaluate the evidence for neonatal (and fetal) disease and, if appropriate, initiate treatment promptly.
Review of maternal background

Antenatal history
Any symptoms or signs consistent with acute toxoplasmosis should be noted, including date of onset. Ten to twenty per cent of all individuals develop cervical lymphadenopathy or a ‘flu-like’ illness, which has a benign, self-limiting clinical course. Generally, however, T. gondii infection is asymptomatic and may go unnoticed. Immunosuppression is a risk factor for reactivation and/or more severe maternal infection and should also be identified.¹

Antenatal investigations
Review of antenatal ultrasound and/or MRI findings is needed as there may be indications of evolving fetal toxoplasmosis, although these are non-specific (box 1).¹⁵⁷

A positive T. gondii-specific IgM result during pregnancy suggests acute T. gondii infection, probably acquired after conception, and an associated risk of transplacental transmission. Previous maternal specimens, such as booking bloods, should be retrospectively tested; however, there are important caveats to interpretation, summarised in table 1.⁶⁷⁹–¹¹ In equivocal cases, further testing should be undertaken either locally or at a national reference laboratory.⁶

T. gondii-specific IgG avidity can help discriminate between past and recently acquired infection; high avidity reliably excludes recent infection. Comparing serial blood results may demonstrate increasing antibody titre (IgM and/or IgG dye test) or confirm seroconversion during pregnancy (table 1).⁶⁷⁹–¹² If infection acquired before conception can be confirmed, the risk to the pregnancy from T. gondii is considered low (in immunocompetent women), that is, T. gondii-specific

<table>
<thead>
<tr>
<th>Laboratory test</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening test for presence of T. gondii-specific antibodies</td>
<td></td>
</tr>
<tr>
<td>T. gondii-specific IgM</td>
<td></td>
</tr>
<tr>
<td>T. gondii-specific IgA</td>
<td></td>
</tr>
<tr>
<td>T. gondii-specific IgG</td>
<td></td>
</tr>
<tr>
<td>Sabin-Feldman dye test</td>
<td></td>
</tr>
<tr>
<td>Avidity test</td>
<td></td>
</tr>
<tr>
<td>T. gondii-specific NAAT</td>
<td></td>
</tr>
</tbody>
</table>

CSF, cerebrospinal fluid; Ig, immunoglobulin; NAAT, nucleic acid amplification test; PCR, Polymerase chain reaction; T. gondii, Toxoplasma gondii.
IgG positive, IgM negative, with or without high IgG avidity on booking or preconception bloods.

Some women may be offered amniocentesis: a positive T. gondii nucleic acid amplification test (NAAT) result on amniotic fluid confirms intrauterine infection. However, a negative result does not exclude fetal infection, particularly if maternal primary infection occurred in the third trimester.

**Treatment during pregnancy**

Treatment given for acute toxoplasmosis in pregnancy should be recorded, including type and duration of therapy, since the interpretation of infant results may be affected. The two regimens often used are spiramycin (fetal propylbactides preventing intrauterine infection) and combined pyrimethamine/sulfadiazine/folic acid (treatment of evolving fetal infection). Cases should be discussed with a fetal medicine expert and local infection specialist (microbiologist or infectious diseases physician). The efficacy of maternal treatment remains unclear and should not preclude treating the infant if appropriate. However, observational studies have demonstrated effective reduction in transplacental transmission and/or severity of clinical manifestations in symptomatic infants; less is known about the impact on non-severe congenital sequelae.

**Assess clinical features in the newborn**

Table 2 identifies key clinical features suggestive of CT although no signs are pathognomonic. The classic triad is considered to be the presence of chorioretinitis, intracranial calcifications and hydrocephalus. However, up to 85% of congenitally infected newborns may have no findings on routine physical examination; more specific testing, primarily examination of cerebrospinal fluid (CSF), neuroimaging and detailed ophthalmological review, is required to demonstrate subclinical end-organ abnormalities, as discussed below. One study demonstrated that up to 40% of infants with confirmed infection had retinal or central nervous system (CNS) abnormalities despite a normal routine initial neonatal examination.

**Arrange urgent postnatal investigations**

**Blood tests**

A basic understanding of the significance of different infant tests is useful (table 1). Paired T. gondii-specific serology from the infant and the mother must be taken at birth (not cord blood). This enables a comparison between the T. gondii-specific IgM, IgA and IgG levels. Significantly raised levels of T. gondii-specific IgM or IgG (more than four times) in the infant compared with the mother are suggestive of congenital infection. Detection of IgM in the neonate, however, should be interpreted with some caution, particularly where highly sensitive IgM tests are employed, since low levels of transplacental leakage can be detected. In such cases, these typically very low levels of maternal IgM disappear from the infant within 1–2 weeks. Detection of IgA in the newborn can also only be considered significant if the mother is IgA negative, since IgA readily crosses the placenta (disappearing by 2 weeks) and, therefore, passive transfer must be excluded (table 1).

Conversely, only 50%–60% of congenitally infected infants will have positive T. gondii-specific IgM or IgA in the first month of life. Where results are negative, repeat testing should be carried out until at least 3 months of age, since seropositivity can be delayed. T. gondii-specific IgG testing should continue beyond this, for example, at 6 and 12 months. In uninfected infants, all maternally acquired IgG should have disappeared by 12 months (table 1). In infected infants treated before, at or soon after birth, a serological response may not occur until treatment is withdrawn. Thus, negative serological findings in such cases cannot exclude congenital infection, and follow-up testing is required after completion of treatment.

Infant specimens found positive on T. gondii NAAT confirm congenital infection. Nevertheless, a blood NAAT may not detect organ-specific disease (including ocular toxoplasmosis). Additional useful blood tests include full blood count, liver function and renal profile. Tests to exclude other congenital infections should also be undertaken, particularly in equivocal cases.

**Lumbar puncture**

Any infant with findings consistent with CT should have a lumbar puncture and CSF sent for protein, glucose, cell count, culture and T. gondii NAAT.
Neurological disease may manifest with mononuclear CSF pleocytosis or raised CSF protein.9 10 18

Neuroimaging
In cases of suspected toxoplasmosis, cranial ultrasound and MRI brain should be arranged urgently, first to detect major structural abnormalities and thereafter to comprehensively describe T. gondii-related pathology, including intracranial calcifications, hydrocephalus, cortical atrophy and microcephaly (figure 1). Detailed MRI views of the globes can detect microphthalmia and of the aqueduct can ascertain the risk of developing hydrocephalus.4 18

Arrange postnatal specialist reviews
Ophthalmology
All newborns at risk of CT should be assessed urgently by an ophthalmologist. Ocular disease, such as chorioretinitis and scarring identified on specialist review, may be the only manifestation of CT, with no other visible clinical findings.15 18 Since these lesions can be delayed, developing later in childhood, repeat ophthalmological assessments should be considered beyond infancy to an age when the child is able to identify significant visual changes (and potentially lifelong).6 7 11 12

Audiology
A hearing evaluation should be arranged, with follow-up testing if infection is confirmed.7

Treat infants with evidence of end-organ disease
The definitive indication for starting therapy in an infant born to a mother with toxoplasmosis in pregnancy is evidence of end-organ disease, with or without confirmed serological or NAAT proof of infection in the neonate (table 3).

The underlying rationale is that newborns with untreated symptomatic CT have a significant risk of developing severe long-term complications, including intellectual, neurological, visual and hearing deficits. Untreated infants with subclinical infection can have similar outcomes, although the risk remains uncertain.7 11 12 19

Data on comparative efficacy of different infant treatment options are limited and protocols are not standardised worldwide.7 13 The preferred regimen in the UK is a combination of sulfadiazine, pyrimethamine

<table>
<thead>
<tr>
<th>Evidence of congenital Toxoplasma gondii infection versus end-organ disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Evidence of congenital infection</strong></td>
</tr>
<tr>
<td><strong>Antenatal</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Postnatal</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Table 3 Evidence of congenital Toxoplasma gondii infection versus end-organ disease

CSF, cerebrospinal fluid; Ig, immunoglobulin; NAAT, nucleic acid amplification test; T. gondii, Toxoplasma gondii. 

Figure 1 Axial T2 (A) and sagittal T1-weighted images (B) of a 1-day-old male newborn with congenital toxoplasmosis show marked hydrocephalus due to aqueduct stenosis (arrow in B) on a background of loss of cerebral white matter. Axial CT of an 11-week-old female infant with congenital toxoplasmosis (C) demonstrates typical periventricular and basal ganglia calcifications (arrows) and dilatation of the ventricles, mainly due to loss of cerebral white matter (‘ex-vacuo’), without radiological signs of acute obstructive hydrocephalus.
and folinic acid for 12 months (box 2), in keeping with recommendations made in many European countries, North America and Australia.6 7 11 12 G6PD deficiency must be excluded prior to administration and steroids may be added for severe ocular disease or high CSF protein (more than 1 g/dL).1 18

There are no randomised controlled trials (RCT) of this combination therapy in infants.13 Previous large cohort studies, particularly in North America, have reported that a 12-month therapeutic course is associated with significantly decreased incidence and severity of long-term sequelae and new-onset ocular disease when compared with untreated historical controls or those treated for a shorter duration.8 11 19 20 In European studies, treatment was often started antenatally precluding reliable determination of the effects of postnatal therapy. Data predominantly demonstrated an improvement in ocular prognosis following early diagnosis and timely initiation of treatment.11 13 A French RCT is currently comparing the efficacy of triple therapy for 3 vs 12 months on the development of chorioretinitis over a 2-year period in infants with non-severe CT (ClinicalTrials.gov NCT01202500).

Despite better outcomes, treated infants are still at risk of developing delayed complications.8 This is because current treatment targets T. gondii tachyzoites (rapidly proliferating developmental stage) but does not successfully eliminate slower-growing, latent bradyzoites established within tissue cysts, particularly in the eye and CNS.1 5 18 Therefore, relapse of ocular (including late-onset retinal lesions) and CNS disease can occur, in some cases even several years after treatment has been completed, potentially requiring retreatment.11 18

**Monitor infants with no evidence of end-organ disease**

Given the paucity of available evidence, there is no clear consensus on the benefit of treating neonates who have been born to a mother with toxoplasmosis in pregnancy and who are asymptomatic without confirmed end-organ disease.7 11–13 Positive fetal or infant serology or NAAT results, although not indications for treatment, are still useful to diagnose T. gondii-specific infection in the infant (table 3) and, therefore, guide longer term follow-up (figure 2).

Most infectious disease paediatricians in the UK would monitor serology and defer treatment, bearing in mind the toxicity of treatment. Close outpatient follow-up is required, only starting treatment if clinically indicated. This decision may vary in other settings.

Figure 2 summarises the step-by-step considerations in the investigation and management of newborns at risk of CT. Interpretation of results and decisions about treatment should be made in conjunction with microbiologists and infectious disease specialists. Families should be fully informed about the risks and benefits of treatment, including limitations of current knowledge and diagnostic tests.

**Follow-up of treated infants**

Close monitoring of infants on treatment for adverse events, disease recurrence, symptom progression and therapeutic response is critical (table 4).7 11 12 Follow-up is recommended in a specialist paediatric infectious diseases clinic. Potential prognostic factors associated with poor outcomes include delay in initiation of treatment (and/or correction of hydrocephalus); prolonged hypoxia or episodes of hypothermia, apnoea and bradycardia at presentation; CSF protein more than 1 g/dL and cerebral atrophy.1

Parents should be offered peer support through networking groups and access to helpful online resources. The UK Tommy’s charity provides online support and comprehensive information for parents (https://www.tommys.org/pregnancy-information/pregnancy-complications/infections-pregnancy/toxoplasmosis-pregnancy).

**CONCLUSION**

When faced with a case of suspected CT, the paediatric team must be aware of the workup required to confirm diagnosis, the significance of the results obtained and the importance of timely treatment to prevent or ameliorate adverse clinical consequences. The key learning points are:

- Positive T. gondii-specific IgM and IgG in pregnancy does not necessarily equate to subsequent congenital toxoplasmosis and further investigation and monitoring of the infant (and fetus) are required.
- A thorough postnatal examination is key, although the majority of infected newborns are asymptomatic on initial assessment but may still develop serious long-term sequelae; ophthalmology review and neuroimaging are necessary to detect subclinical end-organ abnormalities.
- T. gondii NAATs and serial infant T. gondii-specific serology are helpful to diagnose infection, although

---

**Box 2 Suggested treatment regimen for congenital toxoplasmosis**

- Pyrimethamine 1 mg/kg TWICE daily for 2 days.
  - Then 1 mg/kg ONCE daily for 6 months.
  - Then 1 mg/kg THREE times weekly to complete 12 months.
- Sulfadiazine 50 mg/kg TWICE daily for 12 months.
  - Only start after neonatal jaundice resolved.
- Folinic acid (calcium folinate, Leucovorin) given to counteract bone marrow toxicity of pyrimethamine.
  - 5–20 mg THREE times weekly during and for 1 week after pyrimethamine therapy.
  - Dose adjusted to age (5 mg in neonates, 10 mg in infants >1 month) and full blood count (table 3).

Is there evidence of end-organ disease (Table 4)?

**YES**
- Refer to paediatric ID and microbiology teams
- Further investigations: a) Lumbar puncture
  b) Imaging: cranial ultrasound and MRI brain
- Initiation of treatment with appropriate follow-up

**NO**
- Is there evidence of congenital infection (on serology/NAAT, Table 4)?
  **YES**
  - Refer to paediatric ID and microbiology teams
  - Discuss the need for further investigations (e.g. lumbar puncture) and value of starting treatment

  **NO** (or equivocal*)
  - Ongoing clinical review: Monitor for evidence of evolving end-organ disease
  - Serial serology tests e.g. at 1, 3, 6 and 12 months, to demonstrate total loss of any maternal T. gondii-specific antibodies and no production of new T. gondii-specific IgM/IgA by the infant (Table 4)**
  - Serial serology tests e.g.

---

Figure 2  Quick reference guide for paediatricians on the management of neonates born to mothers with suspected or confirmed toxoplasmosis in pregnancy (ie, positive Toxoplasma gondii-specific IgM and IgG serology results). *Equivocal serology results include: isolated positive T. gondii-specific IgG and/or IgM and/or IgA results at birth. **If there is no evidence of evolving end-organ disease, the infant can be discharged from follow-up as soon as all maternal T. gondii-specific antibody is lost, and there is no evidence of new production of T. gondii-specific antibody by the infant. T. gondii, Toxoplasma gondii; ID, infectious diseases; Ig, immunoglobulin; NAAT, nucleic acid amplification test; MRI, magnetic resonance imaging.
Table 4  Assessment of medication toxicity, response to therapy and disease progression in infants treated for congenital toxoplasmosis

| Toxicity                                                                 | ► Full blood count to be done at baseline then during treatment to look for drug-induced neutropenia, aplastic anaemia and haemolysis (if co-existing G6PD deficiency).  
|                                                                          | ► Suggested timing is once weekly when on daily pyrimethamine then monthly if stable.  
|                                                                          | ► Withhold treatment if absolute neutrophil count <0.5 x 10⁹/L but continue folic acid (consider increasing dose up to 20 mg).  
|                                                                          | ► Liver function tests and renal profile to be done at baseline then monthly if stable.  
| Response to therapy                                                      | ► Interval serology testing: T. gondii-specific IgG and IgM every 3 months until therapy is completed then at the end of treatment and at 1, 3 and 6 months off treatment.  
|                                                                          | ► Rebound rise in T. gondii-specific IgM and IgG levels may be seen following treatment; this does not necessarily indicate relapse but more likely reflects a delayed serological response to infection.  
| Disease progression and recurrence                                        | ► Follow-up with paediatric infectious disease specialist team.  
|                                                                          | ► Measurement of head circumference at each outpatient visit.  
|                                                                          | ► Regular ophthalmology and vision assessments throughout treatment and at 3, 6 and 12 months following completion, then at least annually for life (to identify potential late-onset complications).  
|                                                                          | ► Consider neurodevelopmental, neurological and auditory review.  
|                                                                          | ► Inform parents about the risks of development of seizures and/or raised intracranial pressure: ensure they have an emergency action plan.  
|                                                                          | ► Urgently repeat brain imaging if there are any signs/symptoms of raised intracranial pressure.  

Suggested time points only.
Ig, immunoglobulin; T. gondii, Toxoplasma gondii.

there are important caveats to the interpretation of laboratory results.
► Treatment is indicated if there is evidence of end-organ disease.
► End-organ damage, particularly ocular lesions, can present beyond the neonatal period and, therefore, suspected cases must be followed up appropriately.
► Multidisciplinary care is recommended with clear communication encouraged between obstetric, fetal medicine, midwifery, neonatal, laboratory, specialist infectious disease services and parents.

Remaining challenges and future aims
► To accurately characterise the burden of congenital toxoplasmosis worldwide.
► Ongoing review of the potential for prenatal and/or postnatal screening programme in different settings.
► To develop novel medications that are curative and/or vaccinations for prevention of disease.
► To establish a global consensus on type, dosing and duration of treatment.
► To assess the efficacy of treating infected infants with no evidence of end-organ disease or those with equivocal results, including impact on late-onset ocular lesions in childhood/adolescence.
► To formally assess the effectiveness of different strategies for Toxoplasma gondii risk reduction around the time of conception and during pregnancy (eg. education on behaviour modification, food safety practices).

REFERENCES
Best practice and Fifteen-minute consultations

7 Maldonado YA, Read JS. Committee on infectious diseases. diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States. Pediatrics 2017;139:e20163860.
13 Robert-Gangneux F. It is not only the cat that did it: how to prevent and treat congenital toxoplasmosis. J Infect 2014;68 Suppl 1:S125–33.